U.S. Markets closed

Atea Pharmaceuticals, Inc. (AVIR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.88-0.02 (-0.29%)
At close: 04:00PM EST
6.88 0.00 (0.00%)
After hours: 05:50PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.90
Bid6.53 x 1200
Ask7.23 x 2200
Day's Range6.79 - 7.12
52 Week Range6.79 - 94.17
Avg. Volume2,425,582
Market Cap571.747M
Beta (5Y Monthly)N/A
PE Ratio (TTM)22.05
EPS (TTM)0.31
Earnings DateMar 28, 2022 - Apr 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.50
  • GlobeNewswire

    Atea Pharmaceuticals Highlights Strategic Priorities for 2022

    COVID-19: Planning global Phase 2 outpatient trial for bemnifosbuvir (AT-527) designed to support anticipated combination trials HCV: Obtained from Merck an exclusive worldwide license to ruzasvir (RZR), a Phase 2-ready, oral, potent NS5A inhibitor for development in combination with bemnifosbuvir as a pan-genotypic regimen for hepatitis C (HCV) Dengue: Initiating AT-752 Phase 2 proof-of-concept program for dengue fever BOSTON, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq

  • GlobeNewswire

    Atea Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference

    BOSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 8:15 a.m. ET. A live webcast of the presentation will be available here and on the Company’s website at A replay of the webcast will b


    Scoping Out Bargains in Biotech? These 8 Stocks Trade for Less Than Their Cash.

    Atea Pharmaceuticals, Avrobio, Black Diamond Therapeutics, and NextCure are among those we have identified. But there are risks.